Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
about
Invasive candidiasis as a cause of sepsis in the critically ill patientAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Epidemiology of invasive candidiasis: a persistent public health problemIntensive care medicine research agenda on invasive fungal infection in critically ill patients.Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational studyPharmacological advances in the treatment of invasive candidiasis.Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients.Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patientsInvasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013Invasive fungal infections in transplant recipientsClinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patientsPharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Fungal infections in transplant and oncology patients.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.Antifungal clinical trials and guidelines: what we know and do not knowTriazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Burn wound infections.Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisDose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasisDeletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.Voriconazole in the management of nosocomial invasive fungal infections.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Novel strategies to fight Candida species infection.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tabletsVoriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients.
P2860
Q22305429-2F51D8E7-E697-4E29-B195-C3269919BDF6Q24239978-09783C21-3F97-4267-BEF3-968C195CE607Q27009221-26F1273E-C2BA-4715-B95A-2AF1532DDD8BQ28260910-6FB8F0E6-355B-4E73-A102-406532271D7CQ29616758-25B9679F-A500-4E84-BDBD-3D52C2E89A2EQ30235457-BBB8F7C7-5416-4A8B-B4F6-06B9103318A2Q30781344-CD11F04F-58ED-4DAE-A91A-5719CBF30D1BQ33232599-B2CF1333-F8CD-456D-9019-4DB9549DD1F4Q33234912-4E1A3766-68D4-4552-9D4D-8E3A568A69D9Q33257899-BE073503-4559-4A56-AB0B-3E30D7E3B0EEQ33573788-0086D758-AEDE-495F-96DF-41A0406EB345Q33576580-BE97D961-2DC3-4971-9534-28C228786F72Q33695215-58832EC9-3C96-435E-A230-820BD0C305E2Q33841485-177CD75D-2FC4-4BC0-A3F7-BB5FF467E0AFQ33876525-A71B586F-480C-4995-B752-CB35F112EEA2Q33876645-BAE113E8-7982-444D-94C8-C114C9F9303CQ33896940-6D67196B-20E4-4DE8-88C6-0BA5E2DEEE9CQ34006585-555E7099-23FE-40C4-9083-8A13BCC4174DQ34166590-5ECB5B4E-BFF8-4403-AFD0-8EDBEED8A285Q34400255-4FD75E8D-01C9-4915-B426-987889D71A7CQ34430768-3D187416-735D-4708-9977-73FD8DCAA195Q34431984-EB7C6A49-D241-43D5-8992-6411EBC7CB25Q34505582-B73EAB0B-4C5C-4F13-B8D1-CC6751186501Q34546811-79179296-013B-45CA-B8AB-5CA573E3244CQ34647310-FC0379C0-61D9-438C-8820-F8F58942E568Q34724824-B58F52B2-FABD-426D-9405-7B68129550A0Q34737476-6C5A2D30-5509-42A9-9C74-3619FB06EF3BQ34900399-6A0E8C8B-1DF4-49A2-86C7-40717C0BEDD3Q35026481-538A5E15-B0FB-4182-BAEF-94E66383E4BCQ35026516-C1ECAACD-E23B-41F8-B517-5E336DA738A7Q35065740-4812B2F6-F25E-493A-B330-A39F16D8F1A2Q35091585-CEA8FF05-2F54-444F-8931-8F254E071897Q35166823-8A3A11F3-932A-4B9A-BF3E-3DEACE00DB75Q35270270-C02B1B59-79C7-4975-A8D5-0D8175FFA352Q35406737-7EBD3665-E87E-4555-9E3A-D29D553ADCAAQ35635830-BA3339F9-0A80-460E-A66A-4CBA54354ADBQ35647746-A973F3AD-CA3D-48FA-9D1C-EFCE5411C437Q35659502-E35E6095-0EA8-4844-A6CC-E430B7E7A169Q35759094-61764045-ED29-4C77-8A4A-757B72C4143AQ35977947-63C94196-D933-4F97-AB30-46A6067C585E
P2860
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@ast
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@en
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@nl
type
label
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@ast
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@en
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@nl
prefLabel
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@ast
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@en
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@nl
P2093
P3181
P1433
P1476
Voriconazole versus a regimen ...... ndomised non-inferiority trial
@en
P2093
B J Kullberg
E Rubinstein
H T Schlamm
I T Oborska
J D Cleary
L W P Church
P304
P3181
P356
10.1016/S0140-6736(05)67490-9
P407
P50
P577
2005-10-01T00:00:00Z